Bright Minds Biosciences (DRUG) Amortization (2020 - 2026)

Bright Minds Biosciences has reported Amortization for 7 years, with the latest figure at $227.7 million in Q1 2026.

• For the quarter ending Q1 2026, Amortization rose 480.24% year-over-year to $227.7 million; the trailing twelve-month figure through Mar 2026 stood at $227.7 million (up 480.24% YoY), and the FY2025 full-year result was $61.3 million, up 1295.89% from the prior year.
• Amortization for Q1 2026 stood at $227.7 million, up from $65.1 million in the prior quarter.
• The five-year high for Amortization was $227.7 million in Q1 2026, with the low at $4.4 million in Q3 2024.
• Historically, Amortization has averaged $32.0 million across 5 years, with a median of $8.4 million in 2022.
• Annual changes were most pronounced in 2022 — Amortization sank 61.73% — and 2025, when it jumped 1295.89%.
• Bright Minds Biosciences' Amortization stood at $8.4 million in 2022, then tumbled by 40.34% to $5.0 million in 2023, then soared by 729.69% to $41.7 million in 2024, then jumped by 56.2% to $65.1 million in 2025, then jumped by 249.8% to $227.7 million in 2026.
• The last three Amortization figures came in at $227.7 million (Q1 2026), $65.1 million (Q4 2025), and $61.3 million (Q3 2025), per Business Quant data.